Sirolimus reduces polycystic liver volume in ADPKD patients.
about
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseInterventions for preventing the progression of autosomal dominant polycystic kidney diseaseAutosomal dominant polycystic kidney disease: the last 3 yearsPolycystic liver diseases: advanced insights into the molecular mechanismsPPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney diseaseAdvances in the pathogenesis and treatment of polycystic kidney diseaseRapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.Polycystic kidney disease.Isolated polycystic liver disease.ALADIN: wish granted in inherited polycystic kidney disease?Novel targets for the treatment of autosomal dominant polycystic kidney disease.Regulation of renal tubular glucose reabsorption by Akt2/PKBβRandomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.Sirolimus therapy to halt the progression of ADPKD.Treatment strategies and clinical trial design in ADPKDmicroRNA biomarkers in cystic diseases.An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study.ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease.ADPKD: Prototype of Cardiorenal Syndrome Type 4Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks.Polycystic liver disease.Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trialCongenital hepatic fibrosis in autosomal recessive polycystic kidney disease.Medical therapy for polycystic liver disease.Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease2-Hydroxyestradiol slows progression of experimental polycystic kidney diseaseVolume regression of native polycystic kidneys after renal transplantation.Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside.SSAT/AHPBA joint symposium on evaluation and treatment of benign liver lesions.Current insights into renal ciliopathies: what can genetics teach us?Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?Cholangiociliopathies: genetics, molecular mechanisms and potential therapiesAdvances in management of polycystic liver disease.Emerging evidence of a link between the polycystins and the mTOR pathways.Polycystic liver disease presenting as pruritus.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Systematic review: the pathophysiology and management of polycystic liver disease.
P2860
Q24186484-7DD4E7FF-37E4-4C6E-A606-486433E4D514Q24201920-556CD06D-A1EF-4850-819A-EC180CEB7CA9Q24656249-331F9A4F-3809-40E5-A9D3-0C44EA153845Q27001174-4EBA2808-7118-4F8B-9682-7538070A7132Q28742454-DE802439-AABA-4E2B-B8D2-A886294581F2Q33646379-35DF9576-41DC-400B-A7F4-1233B62C4E98Q33702386-377A04DB-70C5-4684-87FB-595700A6F3C7Q33709685-6B591B69-469C-48D3-BF94-D01F457EA311Q33723830-BF630238-0143-4376-ADE4-715267267A65Q33745445-8C934BDC-09E1-47D2-9727-7E8E03B2D199Q33816594-9EC10BCC-033E-445C-B1A1-6729A90343ACQ33976316-1B3E3228-7A2C-4355-BC04-FF22ADA39CE1Q33979298-F2A0B673-5440-47F7-A02A-2BDFC50DAA8EQ33979376-AF187B3F-4606-49BA-ABFF-9118AA1A8CE7Q34024396-3A76D8E9-0FF2-46E7-80D9-2C70A7F8D5BAQ34049572-33061D28-31A4-4CE1-9186-E801F029FF54Q34074513-D9774DB1-E783-4698-8A46-27917914AB55Q34091331-35D09B22-68DD-4C2C-921E-8479D96E5BA1Q34185922-F50C899A-8012-4F80-B80F-2B250F8F300CQ34399971-A5043AA9-8ECD-4E41-803F-FB81685E5AC7Q34475383-5CDF14FA-0403-4F16-A9B7-B79BBF79E878Q34475590-41FC5F75-59F1-4E1C-B74F-E22E6A057A42Q34658323-08837741-C725-438B-BA13-D0108363A5E3Q34933719-1DE6051E-ACF6-42EF-89BD-9E4D039DA7F0Q35619287-75214975-9D2C-477D-879A-EF29F5F86C00Q35655072-A2B3E84E-1B28-4180-AE30-06D18959B9D7Q35873958-0528464F-8B6E-4B29-9461-C0B1728A5288Q35917458-C4479059-2DB2-49C5-A895-FD50E5303187Q35964504-0BAC01D4-165E-4CA1-817A-81E86DBDF0E3Q36435509-9043C5F0-8A06-4ABF-8FC1-883CCA78128DQ36471777-EA863397-D763-436F-BE2C-B0007F355C9BQ36773151-A8EAA4B7-EF23-4124-AC5F-3D4FCAE0B453Q36780455-E01495F3-900A-43A0-B99D-B12930C92C2DQ36968695-4B25C860-BD7C-4656-BE2A-8DE218BEF097Q37317821-1303A2F8-B571-4760-B5EE-7103C6290694Q37345965-2D3ACE3B-D956-4533-9325-53085A362022Q37432510-5E1E7E92-C908-4166-ADF6-2E347634DD63Q37647738-8C5209A3-F2CB-46B7-9A7F-8EF7C60A4120Q37760379-2D3CBEA0-A5D0-4A6D-A89A-A3B9F5772ED7Q37905881-ABD35EF1-6594-49F6-A18F-63A405D1DD5B
P2860
Sirolimus reduces polycystic liver volume in ADPKD patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Sirolimus reduces polycystic liver volume in ADPKD patients.
@ast
Sirolimus reduces polycystic liver volume in ADPKD patients.
@en
type
label
Sirolimus reduces polycystic liver volume in ADPKD patients.
@ast
Sirolimus reduces polycystic liver volume in ADPKD patients.
@en
prefLabel
Sirolimus reduces polycystic liver volume in ADPKD patients.
@ast
Sirolimus reduces polycystic liver volume in ADPKD patients.
@en
P2093
P2860
P356
P1476
Sirolimus reduces polycystic liver volume in ADPKD patients.
@en
P2093
Bernard F King
Fernando G Cosio
Patrick G Dean
Sumedha Kumar
Vicente E Torres
P2860
P304
P356
10.1681/ASN.2007050626
P577
2008-01-16T00:00:00Z